A detailed history of Ever Source Wealth Advisors, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ever Source Wealth Advisors, LLC holds 292 shares of DNLI stock, worth $6,348. This represents 0.0% of its overall portfolio holdings.

Number of Shares
292
Previous 258 13.18%
Holding current value
$6,348
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 11, 2024

BUY
$15.83 - $23.35 $538 - $793
34 Added 13.18%
292 $5,000
Q4 2023

Feb 09, 2024

BUY
$16.2 - $23.18 $680 - $973
42 Added 19.44%
258 $5,000
Q3 2023

Nov 03, 2023

BUY
$20.63 - $30.17 $3,548 - $5,189
172 Added 390.91%
216 $4,000
Q2 2023

Aug 04, 2023

BUY
$23.37 - $32.96 $1,028 - $1,450
44 New
44 $1,000
Q2 2022

Aug 01, 2022

SELL
$20.88 - $35.19 $1,064 - $1,794
-51 Closed
0 $0
Q4 2021

Feb 07, 2022

BUY
$42.59 - $55.02 $2,172 - $2,806
51 New
51 $2,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.92B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Ever Source Wealth Advisors, LLC Portfolio

Follow Ever Source Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ever Source Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ever Source Wealth Advisors, LLC with notifications on news.